Treatment
The approach depends upon the severity of the disease. Plasmapheresis may reduce the levels of cryoglobulin. Any underlying condition should be treated where possible including hepatitis C (1).
Rituximab (a monoclonal antibody targeted to CD20 on B cells) may be considered in selected patients (who do not have evidence of active HIV or hepatitis B infection) with: (2)
- moderate to severe or severe-rapidly progressive MC
- cryoglobulinaemic vasculitis
- comorbidities that preclude other therapies
References
- Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb;63(2):408-17.
- Quartuccio L, Bortoluzzi A, Scirè CA, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol. 2023 Feb;42(2):359-70.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.